National Institute on Drug Abuse; Notice of Meetings

---
identifier: "/us/fr/2017-17662"
source: "fr"
legal_status: "authoritative_unofficial"
title: "National Institute on Drug Abuse; Notice of Meetings"
title_number: 0
title_name: "Federal Register"
section_number: "2017-17662"
section_name: "National Institute on Drug Abuse; Notice of Meetings"
positive_law: false
currency: "2017-08-22"
last_updated: "2017-08-22"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2017-17662"
document_type: "notice"
publication_date: "2017-08-22"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
fr_citation: "82 FR 39877"
fr_volume: 82
---


#  National Institute on Drug Abuse; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01).

*Date:* September 27, 2017.

*Time:* 1:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Shang-Yi Anne Tsai, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 301-827-5842, *[email protected]* .

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Phase II: NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1).

*Date:* December 1, 2017.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

*Contact Person:* Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, *[email protected]* .

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: August 16, 2017.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.